November 2024 FDA Recall Drug by Tailstorm Health Inc
D-0051-2025 - Lack of Sterility Assurance

This Class II drug recall was voluntarily initiated by Tailstorm Health Inc on November 6, 2024 for the product Drug. The FDA reported the reason for recall as lack of sterility assurance. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0051-2025

Reason for Recall
Lack of Sterility Assurance
Initiated
11-06-2024
Reported
11-27-2024
Quantity
27,560 Syringes

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Tailstorm Health INC
Nationwide Within U.S.
BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syringe, Rx Only, Repackaged by: Medivant Healthcare: 24416 N 19th Ave, Phoenix, AZ, NDC 81483-0041-1

Batch or Lot Expiration Information

Lot# : D24005, Exp. Date 20 February 2025; D24006, Exp. Date 21 February 2025; D24007, Exp. Date 22 February 2025; D24008, Exp. Date 19 March 2025; D24009, Exp. Date 20 March 2025; D24012, Exp. Date 25 April 2025.